[Skip to Content]
[Skip to Content Landing]
December 1, 1956


JAMA. 1956;162(14):1308-1309. doi:10.1001/jama.1956.72970310001009

Promazine (Sparine) is 10-(3-dimethylaminopropyl) phenothiazine hydrochloride, one of the newer ataraxic drugs recently introduced into clinical practice. It is chemically related to chlorpromazine, both compounds containing the phenothiazine nucleus. The structure of promazine is the structure of chlorpromazine minus the chlorine atom. Promazine has been used in the management of patients with acute mental disturbances1 and at this stage is not recommended for patients with chronic conditions. Nevertheless, a clinical trial in such patients was planned. In March, 1956, it was decided to give a course of promazine therapy to 97 patients (50 female, 47 male), all with chronic conditions, who had been hospitalized for from 5 to 25 years. So far as is known, there has been no report in the literature of a case of agranulocytosis resulting from promazine therapy. In order to furnish the first known direct evidence of toxic effects of promazine on the bone